Originally posted by Rob
View Post
(DNA 68.93) tumbled in late-day trading Wednesday, after the company's cancer treatment, Avastin, was not approved... The biotechnology company had hoped to gain approval for the drug as a treatment aimed at prolonging the life of breast cancer patients.







Leave a comment: